Dr. Overton's appointment could influence the FDA's approach to drug approvals, medical device regulations, and public health policies. Stakeholders in the pharmaceutical and healthcare industries will closely monitor her policy priorities. Critics may scrutinize her ties to the administration and her potential impact on the agency's independence. The nomination also highlights ongoing debates about the FDA's role in balancing innovation with safety and efficacy.